



OFFICE of the DEPUTY PRIME MINISTER  
MINISTRY for HEALTH  
15, PALAZZO CASTELLANIA, MERCHANTS STREET, VALLETTA, MALTA

**DH Circular 40/2021**  
DH 665/2021

8<sup>th</sup> July 2021

**Attention All:** Consultants  
Medical Officers  
Pharmacists  
Pharmacy Technicians  
Nurses

**Re: Empagliflozin 10mg and 25mg Tablets**

As part of Government's strategy to continue increasing the availability of medicines, it is being brought to your attention that empagliflozin 10mg and 25mg tablets are now available on the Government Formulary List for in-patient and out-patient use.

Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor and can be prescribed by Consultant Endocrinology and Diabetes. Empagliflozin is protocol regulated for Diabetes Mellitus Type 2 as per protocol 182 attached (Annex 1).

For your attention please.

Dr Denis Vella Baldacchino  
Chief Medical Officer

## Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Capsules/Tablets

---

**Prescriber Criteria:** Consultant Endocrinology and Diabetes

**Outpatient and Inpatient use:**

1. Diabetes Mellitus Type 2

Reserved for patients with HbA1c >7% and <10% \* despite treatment with metformin, sulfonylurea or repaglinide who have either:

- Established atherosclerotic cardiovascular disease, heart failure or chronic kidney disease (defined as diabetes with microalbuminuria or macroalbuminuria of lower eGR [ $<60\text{mL}/\text{min}/1.73\text{m}^2$ ] or both)

**Or**

- BMI  $>30\text{kg}/\text{m}^2$  who need to lose weight, or weight gain minimisation.

\* HbA1c blood test **MUST** be attached with the application for the request to be processed

**Duration of Approval:**

1 year